Avecho Biotechnology Limited Asset Resilience Ratio
Avecho Biotechnology Limited asset resilience ratio. Avecho Biotechnology Limited (OEZ) has an Asset Resilience Ratio of 1.18% as of December 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Avecho Biotechnology Limited (OEZ) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Avecho Biotechnology Limited (2017–2018)
Asset resilience ratio of Avecho Biotechnology Limited from 2017 to 2018. This chart shows how Avecho Biotechnology Limited's Asset Resilience Ratio has changed over time. Read Avecho Biotechnology Limited debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Avecho Biotechnology Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see OEZ total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €56.73K | 1.18% |
| Total Liquid Assets | €56.73K | 1.18% |
Asset Resilience Insights
- Limited Liquidity: Avecho Biotechnology Limited maintains only 1.18% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Avecho Biotechnology Limited Industry Peers by Asset Resilience Ratio
Compare Avecho Biotechnology Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
Avecho Biotechnology Limited Asset Resilience Ratio by Year (2017–2018)
Avecho Biotechnology Limited asset resilience ratio by year from 2017 to 2018. The table below shows the annual Asset Resilience Ratio data for Avecho Biotechnology Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | 1.18% | €56.73K ≈ $66.32K |
€4.80 Million ≈ $5.61 Million |
-4.34pp |
| 2017-12-31 | 5.52% | €454.73K ≈ $531.62K |
€8.24 Million ≈ $9.63 Million |
-- |
About Avecho Biotechnology Limited
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic f… Read more